209 related articles for article (PubMed ID: 22781316)
1. Lycorine hydrochloride inhibits metastatic melanoma cell-dominant vasculogenic mimicry.
Liu R; Cao Z; Tu J; Pan Y; Shang B; Zhang G; Bao M; Zhang S; Yang P; Zhou Q
Pigment Cell Melanoma Res; 2012 Sep; 25(5):630-8. PubMed ID: 22781316
[TBL] [Abstract][Full Text] [Related]
2. Lycorine hydrochloride selectively inhibits human ovarian cancer cell proliferation and tumor neovascularization with very low toxicity.
Cao Z; Yu D; Fu S; Zhang G; Pan Y; Bao M; Tu J; Shang B; Guo P; Yang P; Zhou Q
Toxicol Lett; 2013 Apr; 218(2):174-85. PubMed ID: 23376478
[TBL] [Abstract][Full Text] [Related]
3. Jatrorrhizine hydrochloride inhibits the proliferation and neovascularization of C8161 metastatic melanoma cells.
Liu R; Cao Z; Pan Y; Zhang G; Yang P; Guo P; Zhou Q
Anticancer Drugs; 2013 Aug; 24(7):667-76. PubMed ID: 23695011
[TBL] [Abstract][Full Text] [Related]
4. Targeting Syndecan-1, a molecule implicated in the process of vasculogenic mimicry, enhances the therapeutic efficacy of the L19-IL2 immunocytokine in human melanoma xenografts.
Orecchia P; Conte R; Balza E; Pietra G; Mingari MC; Carnemolla B
Oncotarget; 2015 Nov; 6(35):37426-42. PubMed ID: 26460958
[TBL] [Abstract][Full Text] [Related]
5. Expression profiling of Galectin-3-depleted melanoma cells reveals its major role in melanoma cell plasticity and vasculogenic mimicry.
Mourad-Zeidan AA; Melnikova VO; Wang H; Raz A; Bar-Eli M
Am J Pathol; 2008 Dec; 173(6):1839-52. PubMed ID: 18988806
[TBL] [Abstract][Full Text] [Related]
6. [Vasculogenic mimicry--potential target for tumor therapy].
Yue WY; Chen ZP
Ai Zheng; 2006 Jul; 25(7):914-6. PubMed ID: 16831290
[TBL] [Abstract][Full Text] [Related]
7. Selective targeting of angiogenic tumor vasculature by vascular endothelial-cadherin antibody inhibits tumor growth without affecting vascular permeability.
Liao F; Doody JF; Overholser J; Finnerty B; Bassi R; Wu Y; Dejana E; Kussie P; Bohlen P; Hicklin DJ
Cancer Res; 2002 May; 62(9):2567-75. PubMed ID: 11980651
[TBL] [Abstract][Full Text] [Related]
8. Triptonide potently suppresses pancreatic cancer cell-mediated vasculogenic mimicry by inhibiting expression of VE-cadherin and chemokine ligand 2 genes.
Han H; Du L; Cao Z; Zhang B; Zhou Q
Eur J Pharmacol; 2018 Jan; 818():593-603. PubMed ID: 29162433
[TBL] [Abstract][Full Text] [Related]
9. Synergistic effects of the immune checkpoint inhibitor CTLA-4 combined with the growth inhibitor lycorine in a mouse model of renal cell carcinoma.
Li X; Xu P; Wang C; Xu N; Xu A; Xu Y; Sadahira T; Araki M; Wada K; Matsuura E; Watanabe M; Zheng J; Sun P; Huang P; Nasu Y; Liu C
Oncotarget; 2017 Mar; 8(13):21177-21186. PubMed ID: 28416753
[TBL] [Abstract][Full Text] [Related]
10. Dehydroeffusol effectively inhibits human gastric cancer cell-mediated vasculogenic mimicry with low toxicity.
Liu W; Meng M; Zhang B; Du L; Pan Y; Yang P; Gu Z; Zhou Q; Cao Z
Toxicol Appl Pharmacol; 2015 Sep; 287(2):98-110. PubMed ID: 25982451
[TBL] [Abstract][Full Text] [Related]
11. The involvement of apoptosis in melanoma vasculogenic mimicry.
Vartanian AA; Burova OS; Stepanova EV; Baryshnikov AY
Melanoma Res; 2007 Feb; 17(1):1-8. PubMed ID: 17235236
[TBL] [Abstract][Full Text] [Related]
12. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma.
Hendrix MJ; Seftor EA; Hess AR; Seftor RE
Nat Rev Cancer; 2003 Jun; 3(6):411-21. PubMed ID: 12778131
[TBL] [Abstract][Full Text] [Related]
13. Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2).
Hess AR; Seftor EA; Gardner LM; Carles-Kinch K; Schneider GB; Seftor RE; Kinch MS; Hendrix MJ
Cancer Res; 2001 Apr; 61(8):3250-5. PubMed ID: 11309274
[TBL] [Abstract][Full Text] [Related]
14. Ginsenoside Rg3 inhibition of vasculogenic mimicry in pancreatic cancer through downregulation of VE‑cadherin/EphA2/MMP9/MMP2 expression.
Guo JQ; Zheng QH; Chen H; Chen L; Xu JB; Chen MY; Lu D; Wang ZH; Tong HF; Lin S
Int J Oncol; 2014 Sep; 45(3):1065-72. PubMed ID: 24938458
[TBL] [Abstract][Full Text] [Related]
15. Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry.
Hendrix MJ; Seftor EA; Meltzer PS; Gardner LM; Hess AR; Kirschmann DA; Schatteman GC; Seftor RE
Proc Natl Acad Sci U S A; 2001 Jul; 98(14):8018-23. PubMed ID: 11416160
[TBL] [Abstract][Full Text] [Related]
16. Lycorine inhibits melanoma cell migration and metastasis mainly through reducing intracellular levels of β-catenin and matrix metallopeptidase 9.
Zhang P; Zhang M; Yu D; Liu W; Hu L; Zhang B; Zhou Q; Cao Z
J Cell Physiol; 2019 Jul; 234(7):10566-10575. PubMed ID: 30565685
[TBL] [Abstract][Full Text] [Related]
17. Differential role of tissue factor pathway inhibitors 1 and 2 in melanoma vasculogenic mimicry.
Ruf W; Seftor EA; Petrovan RJ; Weiss RM; Gruman LM; Margaryan NV; Seftor RE; Miyagi Y; Hendrix MJ
Cancer Res; 2003 Sep; 63(17):5381-9. PubMed ID: 14500372
[TBL] [Abstract][Full Text] [Related]
18. Angiogenesis in cutaneous malignant melanoma and potential therapeutic strategies.
Basu B; Biswas S; Wrigley J; Sirohi B; Corrie P
Expert Rev Anticancer Ther; 2009 Nov; 9(11):1583-98. PubMed ID: 19895243
[TBL] [Abstract][Full Text] [Related]
19. Molecular plasticity of human melanoma cells.
Hendrix MJ; Seftor EA; Hess AR; Seftor RE
Oncogene; 2003 May; 22(20):3070-5. PubMed ID: 12789282
[TBL] [Abstract][Full Text] [Related]
20. VE-cadherin regulates EphA2 in aggressive melanoma cells through a novel signaling pathway: implications for vasculogenic mimicry.
Hess AR; Seftor EA; Gruman LM; Kinch MS; Seftor RE; Hendrix MJ
Cancer Biol Ther; 2006 Feb; 5(2):228-33. PubMed ID: 16481735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
